JNJJanssen Research & Development, LLCSigning up patients
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 60 (planned)
- Started
- Oct 3, 2025
- Main results expected
- Apr 12, 2028
- Fully finished
- Apr 6, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Minimal Residual Disease (MRD)-negative Complete Response (CR) After Cilta-cel Infusion
Measured over: At least 12 months after Cilta-cel infusion on Day 1
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07149857 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC